COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir (BIOKAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01031849
Recruitment Status : Terminated (patient sample not reached)
First Posted : December 15, 2009
Last Update Posted : April 8, 2013
Information provided by (Responsible Party):
Ines Perez, Hospital San Carlos, Madrid

Brief Summary:
The objective is to analyse the changes in the adipose tissue hystological features and the adipogenesis gene expression and related to inflammation after 48 and 96 weeks after the change from AZT+3TC+ABC (Trizivir®) to a monotherapy treatment with LPV/r (Kaletra®)

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Kaletra Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Análisis de Los Cambios en el Tejido Adiposo de Pacientes Con infección VIH y Lipoatrofia en Tratamiento Con análogos de nucleósidos timidínicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir
Study Start Date : February 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Kaletra, all patients
Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
Drug: Kaletra
Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.

Primary Outcome Measures :
  1. Change in those representative gene expression of adipose tissue toxicity (variable established from those gene involved in adipogenesis, inflammation and metabolism. This gene expression will counted) [ Time Frame: 48 and 96 weeks ]

Secondary Outcome Measures :
  1. Changes in physical fat deposits [ Time Frame: Baseline, 24, 48, 72 and 96 weeks ]
  2. Changes in leptine and adiponectine plasma levels [ Time Frame: baseline, 24, 48, 72 and 96 weeks ]
  3. Patients percentage with virologic response (ARN-VIH< 50 copies/mL) [ Time Frame: 48 and 96 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients infected with VIH-1, documented with a positive HIV-1 antibody test and/or positive PCR, confirmed for HIV-1 RNA.
  • Patients treated with a HAART that should contain AZT+3TC+ABC (Trizivir®)
  • Patients with an indetectable viral load, which will be defined <40 copies/mL within the last six months.
  • Patients with a lipoatrophy clinical evidence (which will be defined as moderate or severe, according to the Lipodystrophy Severity Grading Scale).
  • Men or women aged ≥ 18.
  • For women of childbearing potential, negative urine pregnancy test during the Screening visit.
  • Patients that have signed and dated the Informed consent Form prior to any Study-specific procedure.

Exclusion Criteria:

  • Patients with evidence of protease inhibitors failure, and/or documented evidence of protease gene resistance mutation. This evidence could be prior or during the inclusion period in the Study.
  • Patients who, for any reason could not be treated with LPV/r.
  • Cachexia, defined as an Body Mass Index <17 Kg/m2.
  • Pregnant or breastfeeding women, or women of childbearing potential who do not use the appropriate contraceptive method, according to the Investigator judgment.
  • Clinically relevant disease or condition, according to the Investigator judgment, three months prior to the patient inclusion in the Study.
  • Patients taking the following concomitant medication that could affect the adipocyte function or morphology, such as: insulin, steroids, anabolic steroid, anti-inflammatory medication for more than three months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01031849

Layout table for location information
Fundación Jiménez Díaz
Madrid, Spain, 28040
Hospital Clínico San Carlos
Madrid, Spain, 28040
Sponsors and Collaborators
Ines Perez
Layout table for investigator information
Principal Investigator: Vicente Estrada, MD hospital Clínico San Carlos, Madrid
Layout table for additonal information
Responsible Party: Ines Perez, MD, Hospital San Carlos, Madrid Identifier: NCT01031849    
Other Study ID Numbers: HCSKAL-2009-01
2009-016090-14 ( Other Identifier: EudraCT Number )
First Posted: December 15, 2009    Key Record Dates
Last Update Posted: April 8, 2013
Last Verified: April 2013
Keywords provided by Ines Perez, Hospital San Carlos, Madrid:
HIV 1 patients
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors